Monoclonal antibody · Immune activation, directed at MICA and MICB · developed by Cullinan Therapeutics
Isuventatug (CLN-619) is a human IgG1 monoclonal antibody that binds the alpha3 domain of the stress-induced NKG2D ligands MICA and MICB on tumor cells. It blocks their cleavage by tumor microenvironment proteases, preserving NKG2D engagement that activates NK cells and enables antibody-dependent cell-mediated cytotoxicity. It is being studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06381141 | Phase 1 | Multiple Myeloma | Active not recruiting | CGEM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple Myeloma
Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEM page.
See CGEM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CGEM catalysts and pipeline →